Table 2.
Summary of ICU complications and interventions stratified by EPHX2 genotype
| Characteristics* | EPHX2 Genotype | p-value | ||
|---|---|---|---|---|
| Wild Type (n=57) | K55R (n=14) | R287Q (n=24) | ||
| Mechanically ventilated | 29 (50.8) | 9 (64.3) | 11 (45.8) | 0.54 |
| Duration, hours, med (IQR) | 46 (32–186) | 192 (132–216) | 144 (30–264) | 0.23 |
| Extraventricular drains | 43 (75.4) | 14 (92.9) | 17 (70.8) | 0.27 |
| Stress-induced cardiomyopathy | 4 (7.0) | 2 (14.3) | 2 (8.3) | 0.68 |
| ARDS | 1 (1.8) | 3 (21.4) | 1 (4.2) | 0.012 |
| Neurogenic fever | 8 (14.0) | 4 (28.6) | 5 (20.8) | 0.41 |
| Vasopressor use | 26 (45.6) | 7 (50.0) | 8 (33.3) | 0.51 |
| Hypertonic saline | 44 (77.2) | 9 (64.3) | 16 (66.7) | 0.47 |
| Sodium handling | 0.42 | |||
| CSW | 15 (26.3) | 4 (28.6) | 10 (41.7) | |
| SIADH | 7 (12.3) | 0 (0) | 2 (8.3) | |
| Blood product use | 21 (36.8) | 6 (42.9) | 8 (33.3) | 0.84 |
| 7-day fluid balance, l, mean ± SD | 3.5 ± 3.5 | 4.4 ± 2.1 | 2.7 ± 3.1 | 0.32 |
ARDS acute respiratory distress syndrome, CSW cerebral salt wasting, SIADH syndrome of inappropriate anti-diuretic hormone secretion
*
Data are expressed as n (%) frequency distributions unless otherwise specified